Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively[1].
in vivo
Dostarlimab (200 μg/mouse; i.p.; twice weekly for 35 days) shows antitumor activity in humanized mouse models[1].
Animal Model:
Humanized NOG-EXL mice, A549 and MDA-MB-436 tumor model[1]
Dosage:
200 μg/mouse
Administration:
Intraperitoneal injection; twice weekly for 35 days
Result:
Resulted in great inhibition of tumor growth in an A549 lung cancer model (tumor growth inhibition [TGI] of 62% at termination). The antitumor activity was associated with a reduction in tumor-associated regulatory T cells and a trend toward increased tumor-infiltrating CD8+ T cells. Inhibited tumor growth of MDA-MB-436 breast cancer model (TGI of 53%).
References
[1] Kumar S, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13(1):1954136. DOI:10.1080/19420862.2021.1954136
